Robert Carpenter
Oprichter bij IMMUNEERING CORPORATION
Vermogen: 2 M $ op 31-05-2024
Profiel
Robert J.
Carpenter is the founder.
He founded GelTex Pharmaceuticals, Inc. in 1991 and served as Chairman.
He also founded Procept, Inc. in 1991 and served as President & Chief Executive Officer.
In 1995, he founded VacTex, Inc. and held the position of President & Chief Executive Officer.
In 2008, he founded Immuneering Corp.
and currently serves as Chairman.
In 2011, he founded Lysosomal Therapeutics, Inc. Mr. Carpenter is also the founder of Olaris, Inc., Integrated Genetics, Inc...
In addition to his founding positions, Mr. Carpenter has held several former jobs.
From 1989 to 1991, he worked at IG Laboratories, Inc. as Chairman, Chief Executive Officer & Executive VP.
From 2002 to 2007, he served as Chairman at Peptimmune, Inc. He also held the position of Chairman at Hydra Biosciences, Inc. and Director at Cardiac Science, Inc. From 1994 to 2010, he worked at Genzyme Corp.
as Lead Director.
He has also served as Director at SynapDx Corp., Good Start Genetics, Inc., and ModernaTX, Inc. Additionally, he was President at Boston Medical Investors, Inc.Mr. Carpenter's education history includes a graduate degree from Stanford University, an undergraduate degree from the US Military Academy, and an MBA from Harvard Business School.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 12-06-2024 | 1 148 839 ( 3.87% ) | 2 M $ | 31-05-2024 |
Actieve functies van Robert Carpenter
| Bedrijven | Functie | Begin |
|---|---|---|
| IMMUNEERING CORPORATION | Oprichter | 01-01-2008 |
Eerdere bekende functies van Robert Carpenter
| Bedrijven | Functie | Einde |
|---|---|---|
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Directeur/Bestuurslid | 01-01-2010 |
Peptimmune, Inc.
 Peptimmune, Inc. BiotechnologyHealth Technology Peptimmune was founded in 2002 with technology from the laboratories of Dr. Jack Strominger, Higgins Professor of Biochemistry at Harvard University; and Dr. Hidde Ploegh, from the Whitehead Institute for Biomedical Research. Peptimmune has therapeutics in clinical development for the treatment of multiple sclerosis. Peptimmune's flagship program in multiple sclerosis features PI-2301, which has the opportunity to replace Copaxone® (Teva Pharmaceuticals), the world's leading first-line therapy for the treatment of MS. Peptimmune has broad expertise in MHC Class II molecules and their role in antigen presentation and modulation of immune responses. The Company exploits its proprietary DEEP Technology (Directed Expansion of Epitope Permutation) to design peptides and peptide mixtures for development as therapeutics, diagnostic kits, and as reagents for antibody generation. The Company is building a unique suite of expertise in the manufacture and control of peptide copolymer-based drug products. | Voorzitter | 01-08-2007 |
Cardiac Science, Inc.
 Cardiac Science, Inc. Miscellaneous Commercial ServicesCommercial Services Cardiac has developed RHYTHMx ECD, technology that continuously monitors a patient's heart rhythm and provided defibrillation to help the organ keep a steady beat. Cardiac Science has used the technology to develop an external cardiac defibrillator, the Powerheart, which is used in hospitals. The firm also sold patient monitors and emergency defibrillators, and has developed a small portable defibrillator that can be used by patients in the hospital or at home. Cardiac Science markets its products in more than 50 countries worldwide. | Directeur/Bestuurslid | 02-09-2005 |
GelTex Pharmaceuticals, Inc.
 GelTex Pharmaceuticals, Inc. BiotechnologyHealth Technology GelTex Pharmaceuticals, Inc. was developed non-absorbed, polymer-based pharmaceuticals that selectively bind and eliminate target substances from the intestinal tract. The company is a subsidiary of Geltex Corp. GelTex Pharmaceuticals was founded by Henry E Blair & James B Tananbaum in 1991 and was located in Waltham, MA. | Oprichter | 01-12-2000 |
| VacTex, Inc. | Algemeen Directeur | 01-04-1998 |
Opleiding van Robert Carpenter
| Stanford University | Graduate Degree |
| US Military Academy | Undergraduate Degree |
| Harvard Business School | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| IMMUNEERING CORPORATION | Health Technology |
| Bedrijven in privébezit | 15 |
|---|---|
IG Laboratories, Inc.
 IG Laboratories, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sanofi, IG Laboratories, Inc. is a company that provides genetic testing services. The company is based in Framingham, MA. The company was founded by Peter L. Lanciano. IG Laboratories was acquired by Genzyme Corp., part of Sanofi from April 08, 2011 on October 03, 1995 for $21 million. | Commercial Services |
GelTex Pharmaceuticals, Inc.
GelTex Pharmaceuticals, Inc. BiotechnologyHealth Technology GelTex Pharmaceuticals, Inc. was developed non-absorbed, polymer-based pharmaceuticals that selectively bind and eliminate target substances from the intestinal tract. The company is a subsidiary of Geltex Corp. GelTex Pharmaceuticals was founded by Henry E Blair & James B Tananbaum in 1991 and was located in Waltham, MA. | Health Technology |
Cardiac Science, Inc.
Cardiac Science, Inc. Miscellaneous Commercial ServicesCommercial Services Cardiac has developed RHYTHMx ECD, technology that continuously monitors a patient's heart rhythm and provided defibrillation to help the organ keep a steady beat. Cardiac Science has used the technology to develop an external cardiac defibrillator, the Powerheart, which is used in hospitals. The firm also sold patient monitors and emergency defibrillators, and has developed a small portable defibrillator that can be used by patients in the hospital or at home. Cardiac Science markets its products in more than 50 countries worldwide. | Commercial Services |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Procept, Inc.
 Procept, Inc. Pharmaceuticals: MajorHealth Technology Procept is engaged in the research and development of small molecule therapeutics for the prevention and treatment of chronic and life-threatening immune system disorders. Procept is developing therapeutics for the treatment of autoimmune disease, organ transplant rejection and infectious diseases, such as AIDS and tuberculosis. The company is located in San Diego. CA | Health Technology |
Peptimmune, Inc.
Peptimmune, Inc. BiotechnologyHealth Technology Peptimmune was founded in 2002 with technology from the laboratories of Dr. Jack Strominger, Higgins Professor of Biochemistry at Harvard University; and Dr. Hidde Ploegh, from the Whitehead Institute for Biomedical Research. Peptimmune has therapeutics in clinical development for the treatment of multiple sclerosis. Peptimmune's flagship program in multiple sclerosis features PI-2301, which has the opportunity to replace Copaxone® (Teva Pharmaceuticals), the world's leading first-line therapy for the treatment of MS. Peptimmune has broad expertise in MHC Class II molecules and their role in antigen presentation and modulation of immune responses. The Company exploits its proprietary DEEP Technology (Directed Expansion of Epitope Permutation) to design peptides and peptide mixtures for development as therapeutics, diagnostic kits, and as reagents for antibody generation. The Company is building a unique suite of expertise in the manufacture and control of peptide copolymer-based drug products. | Health Technology |
Hydra Biosciences, Inc.
 Hydra Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Hydra Biosciences, Inc. develops pharmaceutical products. It is focused in major therapeutic areas, which include pain, inflammation, renal, anxiety, and pulmonary diseases. The company was founded by Laurie Bartlett Keating, Dean Y. Li, David E. Clapham, and Mark T. Keating in 2001 and is headquartered in Belmont, MA. | Health Technology |
Boston Medical Investors, Inc.
 Boston Medical Investors, Inc. Investment ManagersFinance Founded in 1994 by Robert J. Carpenter, Boston Medical Investors, Inc. is a privately-held venture capital firm located in Cambridge, Massachusetts. | Finance |
Integrated Genetics, Inc.
 Integrated Genetics, Inc. Pharmaceuticals: MajorHealth Technology Part of Laboratory Corp. of America Holdings, Integrated Genetics, Inc. is a pharmaceutical preparations company. The company is based in Framingham, MA. The company was founded by Robert J. Carpenter. | Health Technology |
SynapDx Corp.
 SynapDx Corp. Miscellaneous Commercial ServicesCommercial Services SynapDx Corp. operates as a laboratory services company which develops a blood-based test for the early detection of autism spectrum disorder. It provides laboratory testing services to physicians who evaluate children for developmental disorders with the initial goal of enabling earlier detection of autism. The company was founded by Stanley N. Lapidus, Jeffrey R. Luber, Graham Gardner and Patrick A. Anquetil in 2010 and is headquartered in Lexington, MA. | Commercial Services |
ModernaTX, Inc.
 ModernaTX, Inc. BiotechnologyHealth Technology Modernatx, Inc. develops messenger RNA therapeutics. Its vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. The company was founded by Derrick J. Rossi, Doug G. Cole, Doug G. Cole, Robert S. Langer, Jr., Noubar Afeyan, and Kenneth R. Chien in 2011 and is headquartered in Cambridge, MA. | Health Technology |
| VacTex, Inc. | |
Lysosomal Therapeutics, Inc.
 Lysosomal Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Lysosomal Therapeutics, Inc. engages in the innovation, research, and development in the field of neurodegeneration. It focuses in lysosomal biology in developing novel small molecules for use in the treatment of neurodegenerative diseases. The company was founded by Dimitri Krainc, Joseph Mazzulli, Henri A. Termeer, Robert J. Carpenter, Peter Wirth, Edmund J. Sybertz, and Kees Cornelis Been in 2011 and is headquartered in Cambridge, MA. | Health Technology |
Olaris, Inc.
 Olaris, Inc. Hospital/Nursing ManagementHealth Services Olaris, Inc. provide cancer treatment services. The company was founded by Elizabeth O'Day, Gerhard Wagner and Bob Carpenter and is headquartered in Cambridge. MA. | Health Services |
Good Start Genetics, Inc.
 Good Start Genetics, Inc. Medical/Nursing ServicesHealth Services Good Start Genetics, Inc. operates as a molecular diagnostics firm. It offers pre-pregnancy diagnostic test services to screen a panel of genetic disorders. The firm also provides clinical laboratory and genetic counseling support services. The company was founded by Eric Boutin, Paris Wallace, and Gregory J. Porreca in December 2007 and is headquartered in Cambridge, MA. | Health Services |
